Abstract Library

#2978 Policy Barriers to Increasing Access to Radioligand Therapy for Neuroendocrine Cancers

Introduction: Radioligand therapy is a relatively new treatment approach used in a small number of neuroendocrine cancers and has been shown to improve overall survival and quality of life. Yet because it uses radioactivity, there are particular barriers to its greater integration into cancer care. As neuroendocrine cancers are rare, it is all the more urgent that these barriers be understood and overcome so that this treatment modality can become available to all patients who may benefit.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Merkel C

Authors: Merkel C, Whicher C, Herrmann K, Jervis N, Ćwikła J,

Keywords: PRRT, peptide receptor radionuclide therapy, radioligand therapy, policy, multidisciplinary care, nuclear medicine, neuroendocrine cancer,

#2959 Synergic Value of 68Ga-DOTATOC PET and MRI in NET Patients Undergoing Simultaneous 68Ga-DOTATOC PET/MRI Scan

Introduction: The simultaneous acquisition of 68Ga-DOTATOC PET and functional MRI has relevant implication in the field of Neuroendocrine Tumours (NETs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Mapelli P, Ironi G, Partelli S, Andreasi V, Muffatti F,

Keywords: 68Ga-DOTATOC, PET/MRI, NET, staging, restaging,

#2805 Small Bowel Neuroendocrine Tumor Metastases: Comparison of Contrast-Enhanced Computed Tomography and 68Ga-DOTATATE PET/CT

Introduction: Most gastrointestinal neuroendocrine tumors (GI-NETs) involve the small intestine (38%) and about 50% of patients present with regional or distant metastases at time of diagnosis [2]. 68Ga-DOTATATE PET/CT provides improved sensitivity and specificity compared to traditional nuclear medicine techniques [4]. However, there is relatively less data comparing performance of 68Ga-DOTATATE PET/CT with contrast-enhanced CT (CECT).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Monahan H, Packard A, Broski S, Goenka A, Kendi T,

Keywords: dotate, computed tomography, neuroendocrine tumor, small bowel, liver, lymph node, 68-gallium,

#2698 Safety and Efficacy of Salvage PRRT with 177Lu-DOTA-Octreotate in Patients with Well-Differentiated Metastatic Neuroendocrine Tumours (NET)

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET). NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Ghaleb N

Authors: Ghaleb N, Dick R, Heraghty N, Zwane-Allen P, Vadrucci M,

Keywords: Nuclear Medicine, Hybrid Imaging, Relapse Therapy, PRRT, Survival, Toxicity,

#2277 Neuroendocrine Tumors Committee of Reference Hospital: Decision-Making Process on the Diagnostic and Therapeutic Approach to Patients with Neuroendocrine Tumors

Introduction: Neuroendocrine tumors (NETs) require a multidisciplinary approach in expert centers due to their rarity, heterogeneity and the lack of evidence about optimal clinical management.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Jimenez-Fonseca P, Valdes N, Fernandez del Valle A, Miguel C, Lauret M,

Keywords: committee, decision-making process, multidisciplinary, tool, treatment,